CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids, has received its first order in Japan through its subsidiary in Yokohama. The order involves installation of the company's analyzer CellaVision® DM96 at the National Hospital Organization Tokyo Medical Center Medience Laboratory.
The Medience laboratory at the Tokyo Medical Center (TMC) has been evaluating the CellaVision DM96 and has shared their user experiences at several hematology meetings in Japan.
"It is very pleasing to present the first results of this past year's investments into establishing CellaVision in Japan," says Yvonne Mårtensson, CEO of CellaVision. "The order is an indication that we are meeting the Japanese customers' high demands on analytical quality and efficiency. The laboratory at the TMC is a good reference to have in our future penetration of the large, potential market in Japan."
The analyzer CellaVision DM96 replaces the manual microscope and contributes to increased efficiency and collaboration between laboratory personnel. By using CellaVision's technology, laboratories can reduce the total labor spent performing manual blood cell differentials and generate reliable and more standardized analyses. The ratios of different white blood cells as well as their appearance are important diagnostic criteria in a number of different diseases, including infections and blood cancers.
So far CellaVision has sold more than 500 analyzers to both hospital laboratories and commercial laboratories, mainly in Europe and North America. In Japan CellaVision's products are sold by the subsidiary CellaVision K.K., which was established in 2008 and was fully operative in the beginning of 2009. CellaVision primarily focuses on the approximately 1000 larger hospital and commercial laboratories in Japan.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
About the National Hospital Organization Tokyo Medical Center Medience Laboratory
National Hospital Organization Tokyo Medical Center (TMC) is a public hospital with approximately 800 beds. For more information visit http://www.ntmc.go.jp
CellaVision AB develops, markets, and sells market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com
CellaVision's share is listed on First North Premier at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.